In vitro investigation of efficient photodynamic therapy using a nonviral vector; Hemagglutinating virus of Japan envelope

Journal of Biomedical Optics

Volumn 17, Issue 7, 2012, Pages

  Sakai, Makoto ^a   Fujimoto, Naohiro ^a   Ishii, Katsunori ^a   Nakamura, Hiroyuki ^b   Kaneda, Yasufumi ^a   Awazu, Kunio ^a  

^a OSAKA UNIVERSITY   (Japan)

^b GAKUSHUIN UNIVERSITY   (Japan)

Author keywords

Drug delivery system; Hemagglutinating virus of Japan envelope; Photodynamic; Protoporphyrin IX; Therapy

Indexed keywords

AMINOLEVULINIC ACID; DRUG CARRIER; VIRUS ENVELOPE PROTEIN; ANTINEOPLASTIC AGENT; PHOTOSENSITIZING AGENT; PROTOPORPHYRIN;

ANIMAL; ARTICLE; CHEMISTRY; EXPERIMENTAL NEOPLASM; GENE VECTOR; HUMAN; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; PHOTOCHEMOTHERAPY; SENDAI VIRUS; TUMOR CELL LINE; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; EXPERIMENTAL MELANOMA; LUNG TUMOR; SPECTROFLUOROMETRY;

AMINOLEVULINIC ACID; ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; GENETIC VECTORS; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; PHOTOCHEMOTHERAPY; SENDAI VIRUS; VIRAL ENVELOPE PROTEINS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; SPECTROMETRY, FLUORESCENCE;

EID: 84872018263     PISSN: 10833668     EISSN: 15602281     Source Type: Journal    
DOI: 10.1117/1.JBO.17.7.077009     Document Type: Article

References (59)

1. J. J. Schuitmaker et al., "Photodynamic therapy: a promising new modality for the treatment of cancer," J. Photochem. Photobiol. B 34(1), 3-12 (1996). (Pubitemid 26334839)
2. C. J. Lightdal et al., "Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial," Gastrointest. Endosc. 42(6), 507-512 (1995).
3. E. Buytaert, M. Dewaele, and P. Agostinis, "Molecular effectors of multiple cell death pathways initiated by photodynamic therapy," Biochim. Biophys. Acta Rev. Canc. 1776(1), 86-107 (2007). (Pubitemid 47332075)
4. D. Mew et al., "Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates," J. Immunol. 130(4), 1473-1477 (1983). (Pubitemid 13159902)
5. A. S. Sobolev, D. A. Jans, and A. A. Rosenkranz, "Targeted intracellular delivery of photosensitizers," Prog. Biophys. Mol. Biol. 73(1), 51-90 (2000). (Pubitemid 30252106)
6. M. Carcenac et al., "Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates," Br. J. Cancer 85(11), 1787-1793 (2001). (Pubitemid 34081528)
7. M. B. Vrouenraets et al., "Development of meta-tetrahydroxyphenyl- chlorin-monoclonal antibody conjugates for photoimmunotherapy," Cancer Res. 59(7), 1505-1513 (1999). (Pubitemid 29160118)
8. M. B. Vrouenraets et al., "Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy," Cancer Res. 61(5), 1970-1975 (2001). (Pubitemid 32692015)
9. M. R. Hamblin, J. L. Miller, and T. Hasan, "Effect of charge on the interaction of site specific photo immunoconjugates with human ovarian cancer cells," Cancer Res. 56(22), 5205-5210 (1996). (Pubitemid 26383037)
10. D. Mew et al., "Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation," Cancer Res. 45(9), 4380-4386 (1985). (Pubitemid 16224901)
11. V. V. Ranade and M. A. Hollinger, "Drug Delivery Systems," 2nd ed., CRC Press, London, United Kingdom (2003).
12. M. Zhang et al., "Fabrication of ZnPc/protein nanohorns for double photodynamic and hyperthermic cancer phototherapy," Proc. Natl. Acad. Sci. USA 105(39), 14773-14778 (2008).
13. A. S. Derycke and P. A. de Witte PA, "Liposomes for photodynamic therapy," Adv. Drug. Deliv. Rev. 56(1), 17-30 (2004). (Pubitemid 38045422)
14. B. Chen, B. Pogue, and T. Hasan, "Liposomal delivery of photosensitizing agents," Exp. Opin. Drug. Deliv. 2(3), 477-487 (2005).
15. J. McCarthy et al., "Polymeric nanoparticle preparation that eradicates tumors," Nano Lett. 5(12), 2552-2556 (2005). (Pubitemid 43088911)
16. I. Roy et al., "Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy," J. Am. Chem. Soc. 125(26), 7860-7865 (2003). (Pubitemid 36782161)
17. K. Maruyama, "PEG-liposome in DDS and clinical studies," Nihon Rinsho 56(3), 632-637 (1998) [Article in Japanese].
18. A. Beilvert et al., "Tyrosine polyethylene glycol (PEG)-micelle magnetic resonance contrast agent for the detection of lipid rich areas in atherosclerotic plaque," Magn. Reson. Med. 62(5), 1195-1201 (2009).
19. Q. Zhang et al., "HVJ envelope vector, a versatile delivery system: its development, application, and perspectives," Biochem. Biophys. Res. Commun. 373(3), 345-349 (2008).
20. H. Maeda, "The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting," Adv. Enzyme Regul. 41(1), 189-207 (2001).
21. H. Mima et al., "Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector," Mol. Cancer Ther. 5(4), 1021-1028 (2006). (Pubitemid 43724603)
22. H. Mima et al., "Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector," J. Gene Med. 7(7), 888-897 (2005). (Pubitemid 41015537)
23. T. Shimbo et al., "Development of a transferrin receptor-targeting HVJ-E vector," Biochem. Biophys. Res. Commun. 364(3), 423-428 (2007). (Pubitemid 350026486)
24. Y. Kaneda et al., "Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system," Mol. Ther. 6, 219-216 (2002).
25. Y. Kaneda and Y Tabata, "Non-viral vectors for cancer therapy," Cancer Sci. 97(5) 348-354 (2006).
26. Y Kondo et al., "Efficient delivery of antibody into living cells using a novel HVJ envelope vector system," J. Immunol. Meth. 332(1-2), 10-17 (2008).
27. H. Suzuki et al., "Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner," FEBS Lett. 582(9), 1325-1329 (2008).
28. M. Kurooka and Y Kaneda, "Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells," Cancer Res. 67(1), 227-236 (2007). (Pubitemid 46142779)
29. M. Tanaka et al., "Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon," Int. J. Cancer 126(8), 1982-1991 (2010).
30. S. A. Friesen et al., "5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review)," Int. J. Oncol. 21(3), 577-582 (2002).
31. J. Kloek et al., "Derivatives of 5-aminolevulinic acid for photodynamic therapy enzymatic conversion into protoporphyrin," Photochem. Photo-biol. 67(1), 150-154 (1998). (Pubitemid 128471973)
32. J. C. Kennedy and H. R. Pottier, "New trends in photobiology: endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy," J. Photochem. Photobiol. B Biol. 14(4), 275-292 (1992).
33. R. H. Pottier et al., "Non-invasive technique for obtaining fluorescence excitation and emission spectra in vivo," Photochem. Photobiol. 44(5), 679-687 (1986).
34. Q. Peng et al., "5-Aminolevulinic acid-based photodynamic therapy," Cancer 79(12), 2282-2308 (1997).
35. K Koenigetal., "Photodynamic tumor therapy and on-line fluorescence spectroscopy after ALA administration using 633 nm light as therapeutic and fluorescence excitation radiation," Proc. SPIE 2078, 2945-2952 (1994).
36. C. Perotti et al., "Porphyrin synthesis from ALA derivatives for photodynamic therapy. In vitro and in vivo studies," Brit. J. Cancer 90, 1660-1665 (2004). (Pubitemid 38648253)
37. Ishihara Sangyo Kaisha, Ltd., "FAQ for GenomONE-Neo EX, version 1.02,".
38. M. E. El-Zaria, H. S. Ban, and H. Nakamura, "Boron-containing protoporphyrin IX derivatives and their modification for boron neutron capture therapy: Synthesis, characterization, and comparative in vitro toxicity evaluation," Chem. Eur. J. 16(5), 1543-1552 (2010).
39. L. L. Anzaldi and E. P. Skaar, "Overcoming the heme paradox: Heme toxicity and tolerance in bacterial pathogen," Infect. Immun. 78(12), 4977-4989 (2010).
40. M. Ito et al., "Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin," J. Gene Med. 7(8), 1044-1052 (2005). (Pubitemid 41195066)
41. Y Okada, "Sendai virus-induced cell fusion," Methods Enzymol. 221, 18-41 (1993). (Pubitemid 23264575)
42. Y Ohgari et al., "Mechanisms involved in (5-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: Relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin," Biochem. Pharmacol. 71(1-2), 42-49 (2005). (Pubitemid 41713525)
43. N. Nishiyama et al., "Enhanced photodynamic cancer treatment by supramolecular nanocarriers charged with dendrimer phthalocyanine," J. Control Release 133(3), 245-251 (2009).
44. S. Herlambang et al., "Disulfide crosslinked polyion complex micelles encapsulating dendrimer phthalocyanine directed to improved efficiency of photodynamic therapy," J. Control Release 155(3), 449-457 (2011).
45. F S. de Rosa et al., "A vehicle for photodynamic therapy of skin cancer influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy," J. Control Release 65(3), 359-366 (2000). (Pubitemid 30122938)
46. F S. de Rosa et al., "In vitro metabolism of 5-ALA esters derivatives in hairless mice skin homogenate and in vivo PpIX accumulation studies," Pharm. Res. 21(12), 2247-2252 (2004). (Pubitemid 40568438)
47. I. E. Furre et al., "Targeting PBR by hexaminolevulinate-mediated photodynamic therapy induces apoptosis through translocation of apoptosis-inducing factor in human leukemia cells," Cancer Res. 65(23), 11051-11060 (2005). (Pubitemid 41713376)
48. H. Nakamura et al., "Highly efficient and minimally invasive in-vivo gene transfer to the mouse uterus using hamagglutinating virus of Japan (HVJ) envelope vector," Mol. Hum. Reprod. 9(10), 603-609 (2003). (Pubitemid 37220820)
49. M. Nishikawa and L. Huang, "Nonviral vectors in the new millennium delivery barriers in gene transfer," Human Gene Ther. 12(8), 861-870 (2001). (Pubitemid 32681851)
50. N. Morishitaa et al., "Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector," Biochem. Biophys. Res. Commun. 334(4), 1121-1126 (2005).
51. T. Kushibiki, M. Sakai, and K. Awazu, "Differential effects of photodynamic therapy on morphologically distinct tumor cells derived from a single precursor cell," Cancer Lett. 268(2), 244-251 (2008).
52. Y Kaneda, Y Saeki, and R. Morishita, "Gene therapy using HVJ-liposomes the best of both worlds?," Mol. Med. Today 5(7), 298-303 (1999). (Pubitemid 29302677)
53. K. Saga et al., "Functional modification of Sendai virus by siRNA," J. Biotech. 133(3), 386-394 (2008). (Pubitemid 50018953)
54. Y Kaneda and Y Tabata, "Non-viral vectors for cancer therapy," Cancer Sci. 97(5), 348-354 (2006).
55. Y Kaneda, S. Yamamoto, and T Nakajima, "Development of HVJ envelope vector and its application to gene therapy," Adv. Genet. 53, 307-332 (2005). (Pubitemid 43580672)
56. M. Gèze et al., "Lysosomes, a key target of hydrophobic photosensiti-zers proposed for photochemotherapeutic applications," J. Photochem. Photobiol. B 20(1), 23-35 (1993). (Pubitemid 23257591)
57. K. Berg and J. Moan, "Lysosomes and microtubules as targets for photochemotherapy of cancer," Photochem. Photobiol. 65(3), 403-409 (1997). (Pubitemid 27158971)
58. I. J. MacDonald et al., "Subcellular localization patterns and their relationship to photodynamic activity of pyropheophorbide-a derivatives," Photochem. Photobiol. 70(5), 789-797 (1999).
59. Y Kawaguchi et al., "Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle," Int. J. Cancer 124 (10), 2478-2487 (2009).